Get to know our clinical trials
Phase II clinical trial of neoadjuvant Durvalumab and platinum-based chemotherapy (CT) in participants with resectable or borderline resectable stage IIB. IIIB Non-Small Cell Lung Cancer (NSCLC)
THE OBJECTIVE OF THIS STUDY IS TO EVALUATE THE EFFICACY AND SAFETY OF NEOADJUVANT DURVALUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY (CT) ADMINISTERED AS INITIAL THERAPY AFTER CANCER DIAGNOSIS, FOLLOWED BY SURGERY AND ADJUVANT DURVALUMAB OR CHEMORADIOTHERAPY (CRT) AND CONSOLIDATION DURVALUMAB ADMINISTERED ALONE AS AN ADDITIONAL MEASURE. THERAPY IN PARTICIPANTS WITH RESECTABLE AND BORDERLINE RESECTABLE STAGE IIB-IIIB NSCLC.
Technical Summary
- STUDY TO EVALUATE DURVALUMAB AND PLATINUM-BASED CHEMOTHERAPY, FOLLOWED BY SURGERY OR CHEMORADIOTHERAPY AND DURVALUMAB, IN PARTICIPANTS WITH RESECTABLE OR BORDERLINE RESECTABLE STAGE IIB-IIIB NON-SMALL CELL LUNG CANCER (MDT-BRIDGE)
- Code EudraCT: 2023-503357-35-00
- Protocol number: D9106C00002
- Promoter: Astra Zeneca AB
- Molecule/Drug: Durvalumab
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.